- Home
- NUWE vs SNGX Comparison
NUWE vs SNGX Comparison
Compare NUWE & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- SNGX
- Stock Information
- Founded
- NUWE 1999
- SNGX 1987
- Country
- NUWE United States
- SNGX United States
- Employees
- NUWE N/A
- SNGX N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- SNGX Health Care
- Exchange
- NUWE Nasdaq
- SNGX Nasdaq
- Market Cap
- NUWE 5.2M
- SNGX 6.1M
- IPO Year
- NUWE N/A
- SNGX 1987
- Fundamental
- Price
- NUWE $0.94
- SNGX $2.21
- Analyst Decision
- NUWE Strong Buy
- SNGX
- Analyst Count
- NUWE 1
- SNGX 0
- Target Price
- NUWE $17.00
- SNGX N/A
- AVG Volume (30 Days)
- NUWE 81.7K
- SNGX 31.7K
- Earning Date
- NUWE 05-06-2025
- SNGX 03-21-2025
- Dividend Yield
- NUWE N/A
- SNGX N/A
- EPS Growth
- NUWE N/A
- SNGX N/A
- EPS
- NUWE N/A
- SNGX N/A
- Revenue
- NUWE $8,740,000.00
- SNGX $119,371.00
- Revenue This Year
- NUWE $22.96
- SNGX N/A
- Revenue Next Year
- NUWE $29.97
- SNGX $119.78
- P/E Ratio
- NUWE N/A
- SNGX N/A
- Revenue Growth
- NUWE N/A
- SNGX N/A
- 52 Week Low
- NUWE $0.90
- SNGX $1.83
- 52 Week High
- NUWE $14.35
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- NUWE 30.44
- SNGX 46.98
- Support Level
- NUWE $0.91
- SNGX $2.25
- Resistance Level
- NUWE $1.03
- SNGX $2.41
- Average True Range (ATR)
- NUWE 0.07
- SNGX 0.11
- MACD
- NUWE -0.02
- SNGX -0.01
- Stochastic Oscillator
- NUWE 16.13
- SNGX 56.45
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).